PROOF, Adiga Collaborate on Biomarkers for Allergy Vaccines | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canada's Centre of Excellence for the Prevention of Organ Failure (PROOF) and Adiga Life Sciences announced today a collaboration to identify proteomic and genomic biomarkers for monitoring the effectiveness of allergy vaccines.

Knowledge gained from the project is expected to lead to a better understanding of how such vaccines work, which will then be used to guide development of molecular tests for diagnosing and managing allergic rhinitis, PROOF said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.